Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

The U.S. Food and Drug Administration reviewed the Company's request for Fast Track designation and concluded that investigation of onvansertib, in combination with FOLFIRI/bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic col... Biopharmaceuticals, Oncology, FDA Cardiff Oncology, Onvansertib, Colorectal Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news